Europe Human Insulin Drugs and Delivery Devices Market, By Drugs (Basal or Long Acting Insulins, Bolus or Fast-Acting Insulins, Traditional Human Insulins, Combination Insulins and Biosimilar Insulins), Device (Insulin Pumps, Insulin Pens, Insulin Syringes and Insulin Jet Injectors), Delivery Devices (Syringes, Pens and Pen Needles), Application (Type II Diabetes and Type II Diabetes), Product (HI Drugs, HI Delivery Devices), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales, Diabetes Clinics/ Centers and Other), End User (Hospitals and Clinics, Homecare and Specialty Centers), Country (Germany, U.K., France, Spain, Italy, Russia, Turkey, Belgium, Nether lands, Switzerland, Rest of Europe) Industry Trends and Forecast to 2028
Market Analysis and Insights : Europe Human Insulin Drugs and Delivery Devices Market
The Europe human insulin drugs and delivery devices market is expected to witness market growth at a rate of 5.68% in the forecast period of 2021 to 2028. Data Bridge Market Research report on human insulin drugs and delivery devices market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in the sedentary lifestyle is escalating the growth of human insulin drugs and delivery devices market.
Insulin is known to be a protein hormone that aids in controlling the blood sugar level in patients whose bodies cannot create enough insulin. Insulin drops the glucose level in the blood by growing glucose uptake into fatty tissues and muscles.
Major factors that are expected to boost the growth of the human insulin drugs and delivery devices market in the forecast period are the increase in the incidence of type 2 diabetes cases around the globe. Furthermore, the developments in the insulin devices design are further anticipated to propel the growth of the human insulin drugs and delivery devices market. Moreover, the suitable reimbursements in healthcare systems across the globe is further estimated to cushion the growth of the human insulin drugs and delivery devices market. On the other hand, the rise in the price regarding the production of insulin drugs and delivery devices is further projected to impede the growth of the human insulin drugs and delivery devices market in the timeline period.
In addition, the increase in the demand for HI analogs will further provide potential opportunities for the growth of the human insulin drugs and delivery devices market in the coming years. However, the occurrence of strict regulations for the launch of medical devices might further challenge the growth of the human insulin drugs and delivery devices market in the near future.
This human insulin drugs and delivery devices market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on human insulin drugs and delivery devices market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Europe Human Insulin Drugs and Delivery Devices Market Scope and Market Size
The human insulin drugs and delivery devices market is segmented on the basis of drugs, device, delivery devices, application, product, distribution channel and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
On the basis of drugs, the human insulin drugs and delivery devices market is segmented into basal or long acting insulins, bolus or fast-acting insulins, traditional human insulins, combination insulins and biosimilar insulins. Basal or long acting insulins is further sub segmented into lantus, levemir, toujeo, tresiba and basaglar. Bolus or fast-acting insulins is further sub segmented into novorapid/novolog, humalog, apidra, fiasp and admelog. Traditional human insulins is further sub segmented into novolin/actrapid/insulatard, humulin and insuman. Combination insulins is further sub segmented into novomix, ryzodeg, xultophy and soliqua or suliqua. Biosimilar insulins is further sub segmented into insulin glargine biosimilars and human insulin biosimilars.
- On the basis of device, the human insulin drugs and delivery devices market is segmented into insulin pumps, insulin pens, insulin syringes, insulin jet injectors. Insulin pumps is further sub segmented into insulin pump devices, insulin pump reservoirs and insulin infusion sets. Insulin pens is further sub segmented into cartridges in reusable pens and disposable insulin pens.
- On the basis of delivery devices, the human insulin drugs and delivery devices market is segmented into syringes, pens, pen needles. Pens is further sub segmented into disposable pens and reusable pens. Pen needles is further sub segmented into standard pen needles and safety pen needles.
- On the basis of application, the human insulin drugs and delivery devices market is segmented into type II diabetes, type II diabetes.
- On the basis of product, the human insulin drugs and delivery devices market is segmented into HI drugs, HI delivery devices.
- On the basis of distribution channel, the human insulin drugs and delivery devices market is segmented into hospital pharmacy, retail pharmacy, online sales, diabetes clinics or centers and other.
- On the basis of end user, the human insulin drugs and delivery devices market is segmented into hospitals and clinics, homecare and specialty centers.
Europe Human Insulin Drugs and Delivery Devices Market Country Level Analysis
The human insulin drugs and delivery devices market is analysed and market size insights and trends are provided by country, drugs, device, delivery devices, application, product, distribution channel and end user as referenced above.
The countries covered in the human insulin drugs and delivery devices market report are the Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.
Germany dominates the human insulin drugs and delivery devices market due to the increase in the incidence of diabetes among the country's population. Furthermore, growing number of patients with Type 1 and Type 2 diabetes will further boost the growth of the human insulin drugs and delivery devices market during the forecast period.
The country section of the human insulin drugs and delivery devices market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare infrastructure growth installed base and new technology penetration
The human insulin drugs and delivery devices market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for human insulin drugs and delivery devices market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the human insulin drugs and delivery devices market. The data is available for historic period 2010-2019.
Competitive Landscape and Europe Human Insulin Drugs and Delivery Devices Market Share Analysis
The human insulin drugs and delivery devices market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to human insulin drugs and delivery devices market.
The major players covered in the human insulin drugs and delivery devices market report are Medtronic, BD, YPSOMED, Insulet Corporation, Biocon, Lilly, Sanofi, Novo Nordisk A/S, Merck Sharp & Dohme Corp., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc and Pfizer Inc. among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-